Pittsburgh plasma p‐tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community
Authors:
Open Access
- 15 July 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (7) , e70409
Abstract
INTRODUCTION: Most available phosphorylated tau (p‐tau)217 immunoassays have similar performance. It is unclear if this is due to the use of the same antibody (the “ALZpath antibody”). We established and evaluated a novel p‐tau217 assay that uses an alternative antibody and benchmarked the results against ALZpath‐p‐tau217. METHODS: After development and analytical validation of the University of Pittsburgh (“Pitt‐p‐tau217”) method, clinical verification was performed in three independent cohorts ( n = 363). RESULTS: Pitt‐p‐tau217 demonstrated high between‐run stability, linearity, and specificity. Clinically, Pitt‐p‐tau217 differentiated neuropathologically confirmed PSEN1 mutation carriers from controls with area under the curve (AUC) = 0.94, and amyloid beta (Aβ) positron emission tomography (PET)–positive from Aβ PET–negative cognitively normal older adults with AUC up to 0.84, equivalent to ALZpath‐p‐tau217 results. Both Pitt‐p‐tau217 and ALZpath‐p‐tau217 were slightly elevated in tau PET–positive versus tau PET–negative participants. Between‐assay correlations were up to 0.93. DISCUSSION: The new Pitt‐p‐tau217 assay exhibits high and reproducible classification accuracies for identifying individuals with biological evidence of Alzheimer's disease, equivalent to the widely used ALZpath‐p‐tau217. Highlights: We designed and developed an alternative assay to quantify plasma phosphorylated tau (p‐tau)217, aiming to enhance accuracy and enable early detection of Alzheimer's disease (AD). Comprehensive analytical and clinical validation demonstrated that the new p‐tau217 assay is a valuable and affordable resource for investigating AD pathophysiology. The new p‐tau217 assay showed similar performance to the established ALZpath assay in staging and monitoring early AD.Keywords
All Related Versions
Funding Information
- National Institute on Aging (R01 AG083874, U24AG082930, P30 AG066468, RF1 AG077474, R01 AG083156, R37 AG023651, R01 AG025516, R01 AG073267, R01 AG075336, R01 AG072641, P01 AG025204)
- National Institute of Neurological Disorders and Stroke (U01 NS131740, U01 NS141777)
- National Institute of Mental Health (R01 MH108509)
This publication has 41 references indexed in Scilit:
- Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortalityNeurology, 2018
- AUC-Maximizing Ensembles through MetalearningThe International Journal of Biostatistics, 2015
- A Practical Guide to Immunoassay Method ValidationFrontiers in Neurology, 2015
- Increased 5-Lipoxygenase Immunoreactivity in the Hippocampus of Patients With Alzheimer's DiseaseJournal of Histochemistry & Cytochemistry, 2008
- Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistryActa Neuropathologica, 2006
- Phases of Aβ-deposition in the human brain and its relevance for the development of ADNeurology, 2002
- Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: INeurology, 2000
- Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer DiseaseJournal of Neuropathology & Experimental Neurology, 1997
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)Neurology, 1991